NCT00003456View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 14, 1995

Primary Completion Date

December 7, 2004

Study Completion Date

December 7, 2004

Conditions
Glioblastoma Multiforme of Brain
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER